Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) FCF Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed FCF Margin for 11 consecutive years, with 301.56% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 32742.0% to 301.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 584.98% through Dec 2025, up 1881.0% year-over-year, with the annual reading at 584.98% for FY2025, 1881.0% up from the prior year.
  • FCF Margin for Q4 2025 was 301.56% at Intellia Therapeutics, up from 558.18% in the prior quarter.
  • The five-year high for FCF Margin was 144.29% in Q4 2021, with the low at 20101.67% in Q3 2021.
  • Average FCF Margin over 5 years is 1674.58%, with a median of 701.02% recorded in 2025.
  • The sharpest move saw FCF Margin tumbled -1997000bps in 2021, then skyrocketed 1952157bps in 2022.
  • Over 5 years, FCF Margin stood at 144.29% in 2021, then crashed by -78bps to 256.32% in 2022, then crashed by -208bps to 790.53% in 2023, then increased by 20bps to 628.98% in 2024, then skyrocketed by 52bps to 301.56% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 301.56%, 558.18%, and 701.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.